3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Glioblastoma
1
Interventions
Temozolomide
43
Magnetic Resonance Spectroscopy
39
Specimen Handling
29
Radiotherapy
19
Radiation
16
Bevacizumab
14
Biopsy
13
Nivolumab
12
Radiosurgery
11
X-Rays
9
Cyclophosphamide
9
Carboplatin
8
Nuclear Medicine Department, Hospital
7
Irinotecan
7
Ipilimumab
6
Cisplatin
6
AZD 6244
6
Vincristine
5
Topotecan
5
Phantoms, Imaging
5
Lomustine
5
Etoposide
5
CTLA-4 Antigen
5
ulixertinib
4
trametinib
4
pembrolizumab
4
olaparib
4
erdafitinib
4
dinutuximab
4
Surveys and Questionnaires
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
varlilumab
×
CNS
×
30 days
×
Clear all
NCT03688178
2026-05-22
DERIVe
Duke University
Phase 2
Active not recruiting
43 enrolled